{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-000393","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.930081+00:00","generated_at":"2026-05-28T05:27:23.804536+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Royalty Pharma to acquire external manager for ~$1.1B, announces $3B buyback","bullets":["Acquires manager RP Management for ~$1.1B: $200M cash, $380M debt assumed, 24.5M RPH shares (4% of shares).","Cumulative cash savings >$1.6B over ten years; >$100M in 2026 rising to >$175M in 2030.","Board approves $3B share repurchase; intends $2B in 2025 subject to market conditions.","Equity consideration vests over 5-9 years; Pablo Legorreta's shares vest in 5 years, others in 9.","Transaction requires shareholder approval; expected close Q2 2025; ~25% of shares committed to vote in favor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-000393","json":"https://secwatch.observer/filing/0000950103-25-000393.json","markdown":"https://secwatch.observer/filing/0000950103-25-000393.md","text":"https://secwatch.observer/filing/0000950103-25-000393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000095010325000393/0000950103-25-000393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000095010325000393/dp223331_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:27:23.804536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}